GENERATION OF 5-FLUOROURACIL + OXALIPLATIN RESISTANT COLON CANCER CELLS: A TOOL TO STUDY CANCER RECURRENCE AND DRUG RESISTANCE

Case ID:
13-1154

Generation of 5-Fluorouracil + Oxaliplatin Resistant Colon Cancer Cells

WSU Tech#: 13-1154

Technology Summary:

A significant obstacle for the successful management of patients with colorectal cancer (CRC) is intrinsic drug resistance or, in patients who respond to chemotherapy, acquired drug resistance. Drug resistance can occur through a variety of mechanisms, including alterations in drug influx, drug efflux, intracellular metabolic activation, and intracellular catabolism, or through alterations in the drug's target. In addition, alterations in genes involved in the regulation of the cell cycle or in DNA damage repair may result in a cell becoming resistant to chemotherapy.

 

The Majumdar Laboratory at Wayne State University (WSU) has developed 2 cell lines: WSU-HCT-116CR and WSU-HT-29CR that can be used as research models of resistance to develop therapeutics able to overcome or bypass resistance mechanisms for colorectal cancer.  Characterization and publications for each line are as follows:

 

WSU-HCT-116CR

 

This cell line is a modified colon cancer HCT-116 (p53+ve wt; k-ras-mutant) that is resistant to the combination of 5-Fluorouracil (5-FU) and Oxaliplatin (Ox) [also referred to as chemo-resistant (CR) colon cancer cells].  The parent cell lines were obtained from the ATCC.

 

 

WSU-HT-29CR

 

This cell line is a modified colon cancer HT-29 (p53-ve; kras-wt) that is resistant to the combination of 5-Fluorouracil (5-FU) and Oxaliplatin (Ox) [also referred to as chemo-resistant (CR) colon cancer cells].  The parent cell lines were obtained from the ATCC.

 

 

 

Benefit Analysis:

 

The overall response rate for advanced colorectal cancer of 5-FU alone is still only 10?15%, and the combination of 5-FU with other anti-tumor drugs has merely improved the response rates to 40?50%. Therefore, new strategies for therapy and resistance reversal are urgently needed.  These models can be used to test compounds in preclinical development to treat advanced CRC.

Stage of Development: Available

 

Patent Status:

 

MTA Only

 

Licensing Opportunity:

Cells are being deposited at the ATCC.  Commercial companies are required to obtain a license from WSU.

Contact for Further Information:  

 Frank Urban, MS, CBA, BA.   email: frank.urban@wayne.edu   Phone (mobile): (734) 355-0730

Patent Information:
For Information, Contact:
John Shallman
Wayne State University
dd2514@wayne.edu
Inventors:
Adhip Majumdar
Yingjie Yu
Keywords: